Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

4,793 total articles

Qualcomm Breakout: Buy the Pullback After a Fresh 52-Week High

Qualcomm Breakout: Buy the Pullback After a Fresh 52-Week High

Qualcomm pushed to a new 52-week high on 05/11/2026, and despite a sharp marketwide sell-off on 05/12/2026 it retains bullish technicals and growing AI/data-center interest. This trade targets a mid-term continuation of the breakout with a clear entry, stop and target calibrated to price action and recent technical support.

Arrowhead at an Inflexion - RNAi Momentum Meets Real Data

Arrowhead at an Inflexion - RNAi Momentum Meets Real Data

Arrowhead (ARWR) is trading near a new 52-week high after positive early obesity trial data and sustained technical strength. The market cap is roughly $11.1B while the pipeline (ARO-INHBE, ARO-ALK7 and multiple ARO candidates) gives multiple clinical and commercial paths. This trade idea lays out a risk-managed long with entry, stop and target and…

GROY — Cash Flow Is Real; A Speculative Buy at $3.70 for a Re-rate

GROY — Cash Flow Is Real; A Speculative Buy at $3.70 for a Re-rate

Gold Royalty (GROY) reported record preliminary Q1 2026 revenue of $7.2M and 1,920 GEOs, validated 2026 guidance and removed a major overhang by eliminating convertible debentures and upsizing its credit line to $100M. That combination makes positive cash flow and growth plausible in 2026, creating a path to re-rating from current ~$854M market cap…

Vistra: Powering AI Demand into a Tactical Long with Defined Risk

Vistra: Powering AI Demand into a Tactical Long with Defined Risk

Vistra (VST) sits at the intersection of secular electricity demand for AI/data centers and a stable generation base. The stock is down from its 52-week high, trading at $146.66 with a $49.45B market cap and a P/E of 25.4. We recommend a tactical long with clear entry, stop and target, taking advantage of recent weakness and multiple visible cataly…

Mirum Pharmaceuticals: Rare-Disease Platform, Not a One-Drug Story

Mirum Pharmaceuticals: Rare-Disease Platform, Not a One-Drug Story

Mirum (MIRM) has moved from a single-franchise story into a broader rare-liver disease platform. Revenue growth and an expanding pipeline support upside, but integration costs from the $620M Bluejay deal and conservative 2026 guidance keep risk elevated. Trade idea: enter at current levels, protect with a measured stop, and target meaningful multip…

Lumentum (LITE): Buy the Optics Bottleneck — Photonics Are Becoming the Next Infrastructure Constraint

Lumentum (LITE): Buy the Optics Bottleneck — Photonics Are Becoming the Next Infrastructure Constraint

Lumentum sits at the center of the AI data center supply chain: lasers, transceivers and photonic components that move massive amounts of data. With a recent run and strategic investments from hyperscaler partners, the business is reporting backlog and capacity tightness that could sustain revenues for years. The valuation is rich, which raises exe…

Vistra's Hidden Leverage: Nuclear Deals Could Re-rate the Stock

Vistra's Hidden Leverage: Nuclear Deals Could Re-rate the Stock

Vistra (VST) sits at an overlooked intersection: a diversified generation fleet and growing long-term power deals that increasingly include nuclear supply for hyperscale data centers. The market has punished the name on near-term regulatory noise and earnings misses, but the fundamentals and corporate positioning argue for a tactical long trade ove…

Kosmos 1Q26: A 16% Pullback to Buy — Mid-Term Swing Setup

Kosmos 1Q26: A 16% Pullback to Buy — Mid-Term Swing Setup

Kosmos plunged roughly 16% after the 05/05/2026 1Q26 results. That drop creates a controlled-risk long opportunity around $3.00. The company still carries leverage, but recent share issuance raised ~$185M to cut commercial debt, production trends show recovery potential, and the stock trades near a 52-week high of $3.32. We outline an actionable mi…

Alphabet: Let Winners Run — Buy the Momentum, Trim on Exhaustion

Alphabet: Let Winners Run — Buy the Momentum, Trim on Exhaustion

Alphabet is trading near $387 after a rapid multi-quarter rebound from last year’s lows. Fundamentals - including $64.4B in free cash flow and a dominant Search franchise - justify holding through an AI-led reacceleration. Technicals show momentum but rising RSI warns of near-term stretch. This trade idea recommends entering at $387.25, a stop at $…

AbbVie's Growth Engine Is Scaling Faster Than The Street Expects

AbbVie's Growth Engine Is Scaling Faster Than The Street Expects

AbbVie is reporting accelerating top-line momentum from its immunology franchise while generating substantial free cash flow and paying a reliable dividend. With Q1 revenue of $15.0B, combined Skyrizi and Rinvoq sales now forecast above $31B in 2026, and $17.8B of free cash flow on the balance sheet, the setup supports a long trade at $207.10 with …

Moody's: Market Fear Overdone — Buy the Pullback for a Re-rating

Moody's: Market Fear Overdone — Buy the Pullback for a Re-rating

Moody's (MCO) is trading like a cyclical tech name despite a durable, high-margin ratings and analytics franchise. At ~$453, the stock prices in a material slowdown and elevated regulatory risk. We think much of that downside is already reflected in valuations: MCO generates roughly $2.75B in free cash flow, sports an ROE north of 80%, and carries …